StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
RHK.DE$12.40-1.60%
Fair $12.40+0.0%

RHK.DE

RHÖN-KLINIKUM Aktiengesellschaft

Healthcare / Medical Care FacilitiesXETRA

$12.40

-0.20 (-1.60%)

Fairly Valued+0.0%Fair Value $12.40Fund rank 34/100 · Data gapFallback financials|
SA 50/C
F-Score: 8/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 25% · confianza 25%

FCF escenarios

weak_data · normalized FCF $46.2M · quality 66.3/100

Data gap 34/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 57/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

50/100

C

Piotroski

8/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is 3.3%, below the 5% threshold
Thesis & Journal · RHK.DELocal privado en este navegador · RHÖN-KLINIKUM Aktiengesellschaft
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$830M

P/E

21.8x

↑

EV/EBITDA

5.7x

↓

ROE

3.3%

↑

Gross Margin

10.8%

↓

Debt/Equity

0.12

↓
52-Week Range$12
$11$13

TradingView lightweight chart

RHK.DE price, volumen y niveles de valoración

Último $12.30Periodo +154.2%
Fair value: $12.40

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2021–2024 · 3 años de histórico normalizado

Revenue CAGR

+4.4%

FCF CAGR

+42.7%

FCF margin

3.6%

FCF / Net income

1.32x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.60B · net income $43.4M · FCF $57.2M

2021-FY → 2024-FY

Gross margin

10.8%-3.3% pts

Operating margin

2.4%+0.2% pts

Net margin

2.7%+0.7% pts

FCF margin

3.6%+2.2% pts
MetricTTM
2024
2023
2022
2021
Income Statement
Revenue$1.60B$1.60B$1.46B$1.45B$1.40B
Net Income$43.4M$43.4M$38.7M$25.1M$28.3M
EBITDA$122.2M$122.2M$117.0M$107.3M$101.2M
EPS0.650.650.580.380.42
Gross Margin10.8%10.8%10.2%13.8%14.1%
Operating Margin2.4%2.4%2.0%2.5%2.1%
Net Margin2.7%2.7%2.6%1.7%2.0%
Balance Sheet
Debt/Equity0.120.120.120.130.13
Current Ratio2.572.57———
Cash Flow
Free Cash Flow$57.2M$57.2M$46.2M$2.1M$19.7M
Returns
ROE3.3%3.3%3.1%2.1%2.4%
Valuation
P/E21.7521.7517.4139.4734.95
EV/EBITDA5.735.735.3010.1110.04
P/B0.640.640.540.820.82
Growth & Yield
Revenue Growth9.0%9.0%1.2%3.1%—
EPS Growth12.1%12.1%52.6%-9.5%—
Dividend Yield1.6%1.6%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

19.2%

exigente

EPS terminal req.

$1.10

Spread vs growth

-7.1%

5Y implied EPS CAGR

15.4%

exigente

EPS terminal req.

$1.33

Spread vs growth

-3.3%

10Y implied EPS CAGR

12.7%

razonable

EPS terminal req.

$2.14

Spread vs growth

-0.6%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -1.5%

Total return

-1.5%

Start / end P/E

21.9x → 18.9x

EPS bridge

0.58 → 0.65

Residual

-1.6%

EPS growth+12.1%
Multiple rerating-13.6%
Dividend+1.6%
Residual / FX / buybacks / cross-term-1.6%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.